SCHEMBL16574201

SCHEMBL16574201

CCN(CC)C(=O)c1cccc(-c2cc(Cl)ccc2C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.55
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 5/20 0.53
LMNA P02545 3/20 0.52
TSHR P16473 1/20 0.52
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
MAPT P10636 2/20 0.46
NR1H2 P55055 1/20 0.44
NR1H3 Q13133 1/20 0.44
BRD4 O60885 1/20 0.44
TAF1 P21675 1/20 0.44
CECR2 Q9BXF3 1/20 0.44
BRD9 Q9H8M2 1/20 0.44
S1PR4 O95977 1/20 0.42
HSD11B1 P28845 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
SUCNR1 Q9BXA5 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21164548 0.87 HPGD (0.53) HPGDTDP1ALDH1A1LMNATSHR
SCHEMBL16574197 0.85 CECR2 (0.48) BRD4TAF1CECR2BRD9S1PR4
SCHEMBL21508145 0.84 HPGD (0.39) HPGDTDP1ALDH1A1LMNATSHR
SCHEMBL18713573 0.84 HPGD (0.50) HPGDTDP1ALDH1A1LMNATSHR
SCHEMBL16574048 0.80 RXRA (0.57) S1PR4SUCNR1L3MBTL1CYP3A4NPC1
SCHEMBL16574049 0.80 TRPV1 (0.50) HPGDTSHRMAPTSMN1; SMN2NPC1
SCHEMBL5432092 0.80 HPGD (0.77) HPGDTDP1ALDH1A1LMNATSHR
SCHEMBL16574051 0.79 PARP1 (0.57) BRD4S1PR4SUCNR1
SCHEMBL7172344 0.78 S1PR4 (0.46) HPGDLMNAMAPTS1PR4SMN1; SMN2
SCHEMBL16574196 0.77 S1PR4 (0.54) ALDH1A1TAF1S1PR4SMN1; SMN2SUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
US-20210205305-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2021-07-08 US disclosed
US-10946018-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ROIVANT SCIENCES GMBH (CH) 2021-03-16 US disclosed
US-20200237760-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ROIVANT SCIENCES GMBH (CH) 2020-07-30 US disclosed
US-10660893-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ROIVANT SCIENCES, GmbH (CH) 2020-05-26 US disclosed
US-20190282575-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2019-09-19 US disclosed
US-10350208-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ROIVANT SCIENCES GMBH (CH) 2019-07-16 US disclosed
US-20180092918-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2018-04-05 US disclosed
US-9750740-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors Kanos Pharmaceuticals, Inc. (US) 2017-09-05 US disclosed
US-20170095476-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2017-04-06 US disclosed
US-9512122-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors KAROS PHARMACEUTICALS, INC. (US) 2016-12-06 US disclosed
US-20160096836-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2016-04-07 US disclosed
US-9199994-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors KAROS PHARMACEUTICALS, INC. (US) 2015-12-01 US disclosed
US-20150080393-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2015-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10660893-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-20150080393-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-20200237760-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-20180092918-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-20170095476-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-20210205305-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-10350208-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-20160096836-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-20190282575-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885
US-10946018-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A HPGD 140/4885TDP1 1225/4885ALDH1A1 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.